References
- Bauer RM, Grabbert MT, Klehr B, et al. 36-month data for the AdVance XP male sling: results of a prospective multicentre study. BJU Int. 2017 Apr;119(4):626-30.
- AdVance™ XP Male Sling System Instructions for Use. Boston Scientific Corporation. 2018.
- Rehder P, Haab F, Cornu JN, et al. Treatment of post-prostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3-year follow up. Eur Urol. 2012 Jul;62(1):140-5.
- Welk B, Herschorn, S. The male sling for post-prostatectomy urinary incontinence: a review of contemporary sling designs and outcomes. BJU Int. 2012 Feb;109(3):328-44.
- Sturm RM, Guralnick ML, Stone AR, et al. Comparison of clinical outcomes between “ideal” and “nonideal” transobturator male sling patients for treatment of post prostatectomy incontinence. Urol. 2014 May;83(5):1186-8.
*Patient satisfaction rates reflect research results with use of the AdVance Male Sling
Your doctor is your best source for information on the risks and benefits of the AdVance™ XP Male Sling System. Talk to your doctor for a complete listing of risks, warnings and important safety information.
The AdVance™ XP Male Sling System is intended for the treatment of male stress urinary incontinence (SUI). Potential risks may include inability to urinate (urinary retention), return to incontinence, infection, erosion, device migration, pelvic organ dysfunction, bleeding, and pain. These devices are contraindicated for patients with urinary tract infections, blood coagulation disorders, a compromised immune system or any other condition that would compromise healing, with renal insufficiency, and upper urinary tract relative obstruction. MH-557011-AB
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.